Answers are grounded in this paper and cite their sources.
Introduction: Leishmaniasis, and most tropical diseases, are rare/orphan diseases in the developed world but not rare worldwide. Classic treatment is with parenteral agents, namely, pentavalent antimony and amphotericin B deoxycholate. Miltefosine is the first oral agent for all forms of leishmaniasis. The target regimen is 2.5 mg/kg/day for 28 days, with a maximum dose of 150 mg/day (one 50 mg capsule each with breakfast, lunch and dinner).Areas covered: Clinical studies visceral, cutaneous and mucosal leishmaniasis treated with miltefosine.Expert opinion: The 2014 FDA approval of the miltefosine New Drug Application for visceral, cutaneous and mucosal leishmaniasis was a breakthrough in several ways. In a clinical sense, miltefosine was recognized in the US, after previously being approved in Europe and in the developing world, as the first oral treatment for any form of leishmaniasis. In a regulatory sense, miltefosine was the first drug solely developed for leishmaniasis. In a financial sense, the $125 million sale of miltefosine’s Tropical Disease Priority Review Voucher created a financial incentive for all tropical disease products. Clinical issues remaining post-approval include generalizability of efficacy data generated against the specific species evaluated in registration documents to the large number of species worldwide and tolerance issues partially addressed pre-registration.
No takes yet. Share an insight, caveat, or question.
Jonathan Berman (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: